The DOI matches its Crossref record; 40 of the 41 references it cites were found in a registry or an index.
Early and protective microglial activation in Alzheimer’s disease: a prospective study using18F-DPA-714 PET imaging
Open accessAbstract
While emerging evidence suggests that neuroinflammation plays a crucial role in Alzheimer's disease, the impact of the microglia response in Alzheimer's disease remains a matter of debate. We aimed to study microglial activation in early Alzheimer's disease and its impact on clinical progression using a second-generation 18-kDa translocator protein positron emission tomography radiotracer together with amyloid imaging using Pittsburgh compound B positron emission tomography. We enrolled 96 subjects, 64 patients with Alzheimer's disease and 32 controls, from the IMABio3 study, who had both (11)C-Pittsburgh compound B and (18)F-DPA-714 positron emission tomography imaging. Patients with Alzheimer's disease were classified as prodromal Alzheimer's disease (n = 38) and Alzheimer's disease dementia (n = 26). Translocator protein-binding was measured using a simple ratio method with cerebellar grey matter as reference tissue, taking into account regional atrophy. Images were analysed at the regional (volume of interest) and at the voxel level. Translocator protein genotyping allowed the classification of all subjects in high, mixed and low affinity binders. Thirty high+mixed affinity binders patients with Alzheimer's disease were dichotomized into slow decliners (n = 10) or fast decliners (n = 20) after 2 years of follow-up. All patients with Alzheimer's disease had an amyloid positive Pittsburgh compound B positron emission tomography. Among controls, eight had positive amyloid scans (n = 6 high+mixed affinity binders), defined as amyloidosis controls, and were analysed separately. By both volumes of interest and voxel-wise comparison, 18-kDa translocator protein-binding was higher in high affinity binders, mixed affinity binders and high+mixed affinity binders Alzheimer's disease groups compared to controls, especially at the prodromal stage, involving the temporo-parietal cortex. Translocator protein-binding was positively correlated with Mini-Mental State Examination scores and grey matter volume, as well as with Pittsburgh compound B binding. Amyloidosis controls displayed higher translocator protein-binding than controls, especially in the frontal cortex. We found higher translocator protein-binding in slow decliners than fast decliners, with no difference in Pittsburgh compound B binding. Microglial activation appears at the prodromal and possibly at the preclinical stage of Alzheimer's disease, and seems to play a protective role in the clinical progression of the disease at these early stages. The extent of microglial activation appears to differ between patients, and could explain the overlap in translocator protein binding values between patients with Alzheimer's disease and amyloidosis controls.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Aβ itself acts as a proinflammatory agent, activating many inflammatory components.”
From Clinical trials of new drugs for Alzheimer disease (2020) · cites this paper as [26]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In the early stages of AD, initial microglial activation may serve a protective role (anti-neuroinflammatory), whereby it tries to clear the amyloid and release nerve growth factors. However, when Aβ or other toxic products over-accumulate, proinflammatory phenotypes are activated, which damage the neurons [26].”
From Clinical trials of new drugs for Alzheimer disease (2020) · cites this paper as [26]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Furthermore, the brains of patients with AD exhibited evidence of sustained inflammation.”
From Clinical trials of new drugs for Alzheimer disease (2020) · cites this paper as [26]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“[18F]DPA-714 was extensively studied in preclinical and clinical models [58–61], as a biomarker of neuroinflammation in various human CNS disorders [58].”
From Neuron secrete exosomes containing miR-9-5p to promote polarization of M1 microglia in depression (2022) · cites this paper as [58]
Experimental — accuracy not yet measuredIn the citing paper
“Furthermore, early neuroinflammation has been shown to be an adaptive mechanism by microglia that protects against AD pathology by reducing the levels of Aβ and tau.118–120”
From Microbiota–gut–brain axis and its therapeutic applications in neurodegenerative diseases (2024) · cites this paper as [120]
In the citing paper
“In vivo imaging shows that microglia activation precedes the onset of AD (100) and is paralleled by increased levels of inflammatory markers in the cerebrospinal fluid (101)”
From Microglia in Alzheimer's disease (2017) · cites this paper as [100]
In the citing paper
“in MCI, microglial activation was positively correlated with cognition and gray matter volume, suggesting that microglial activation plays a protective role in the early phase of clinically apparent disease (100).”
From Microglia in Alzheimer's disease (2017) · cites this paper as [100]
In the citing paper
“Of relevance, PET studies have indicated increased microglia activation in the precuneus and parietal cortex in AD.47,48”
From CSF biomarkers of neuroinflammation and cerebrovascular dysfunction in early Alzheimer disease (2018) · cites this paper as [48]
In the citing paper
“Another study that divided AD subjects into fast decliners and slow decliners measured a higher TSPO signal in the brains of slow decliners, consistent with a protective role for microglial activation even in stages of AD when dementia is evident (Hamelin et al., 2016).”
From Microglia in Alzheimer’s disease (2018) · cites this paper as Hamelin et al., 2016
In the citing paper
“This is consistent with the finding that early microglial activation in response to amyloid plaques, as assessed by in vivo microglial imaging studies, is correlated with increased grey matter volume and reduced rate of cognitive decline46,47.”
In the citing paper
“Methods to image microglia exist and are being used to test the effect of treatments on microglia205–210.”
From Microglial signatures and their role in health and disease (2018) · cites this paper as [209]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Neuroinflammation in Alzheimer's disease
Heneka, M. T., Carson, M. J., Khoury, J. E., Landreth, G. E., Brosseron, F., Feinstein, D. L., Jacobs, A. H., Wyss-Coray, T., Vitorica, J., Ransohoff, R. M., et al. (2015) · The Lancet Neurology · doi:10.1016/s1474-4422(15)70016-5 · Cited by 6,226
TREM2 Variants in Alzheimer's Disease
Guerreiro, R., Wojtas, A., Bras, J., Carrasquillo, M., Rogaeva, E., Majounie, E., Cruchaga, C., Sassi, C., Kauwe, J. S. K., Younkin, S., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1211851 · Cited by 3,020
Revising the definition of Alzheimer's disease: a new lexicon
Dubois, B., Feldman, H. H., Jacova, C., Cummings, J. L., DeKosky, S. T., Barberger-Gateau, P., Delacourte, A., Frisoni, G., Fox, N. C., Galasko, D., et al. (2010) · The Lancet Neurology · doi:10.1016/s1474-4422(10)70223-4 · Cited by 1,869
Self-citationIn-vivo measurement of activated microglia in dementia
Cagnin, A., Brooks, D. J., Kennedy, A. M., Gunn, R. N., Myers, R., Turkheimer, F. E., Jones, T., & Banati, R. B. (2001) · The Lancet · doi:10.1016/s0140-6736(01)05625-2 · Cited by 1,054
Alzheimer’s Disease Risk Gene CD33 Inhibits Microglial Uptake of Amyloid Beta
Griciuc, A., Serrano-Pozo, A., Parrado, A. R., Lesinski, A. N., Asselin, C. N., Mullin, K., Hooli, B., Choi, S. H., Hyman, B. T., & Tanzi, R. E. (2013) · Neuron · doi:10.1016/j.neuron.2013.04.014 · Cited by 1,004
Microglia: Scapegoat, saboteur, or something else?
Aguzzi, A., Barres, B. A., & Bennett, M. L. (2013) · Science · doi:10.1126/science.1227901 · Cited by 836
The peripheral benzodiazepine binding site in the brain in multiple sclerosis
Banati, R. B., Newcombe, J., Gunn, R. N., Cagnin, A., Turkheimer, F., Heppner, F., Price, G., Wegner, F., Giovannoni, G., Miller, D. H., et al. (2000) · Brain · doi:10.1093/brain/123.11.2321 · Cited by 661
Conversion of amyloid positive and negative MCI to AD over 3 years
Okello, A., Koivunen, J., Edison, P., Archer, H. A., Turkheimer, F., Någren, K., Bullock, R. M., Walker, Z., Kennedy, A. M., Fox, N. C., et al. (2009) · Neurology · doi:10.1212/wnl.0b013e3181b23564 · Cited by 537
Lopresti, B. J., Klunk, W. E., Mathis, C. A., Hoge, J. A., Ziolko, S. K., Lu, X., MELTZER, C. C., Schimmel, K., Tsopelas, N. D., DeKosky, S. T., et al. (2005) · PubMed · Cited by 536
Edison, P., Archer, H. A., Gerhard, A., Hinz, R., Pavese, N., Turkheimer, F. E., Hammers, A., Tai, Y. F., Fox, N., Kennedy, A., et al. (2008) · Neurobiology of Disease · doi:10.1016/j.nbd.2008.08.001 · Cited by 513
Flagged first, then by citations
1 of the 41 references couldn’t be matched to a known paper.
Cited by
Sorted by citations
Neuroinflammation and microglial activation in Alzheimer disease: where do we go from here?
Leng, F., & Edison, P. (2021) · Nature Reviews Neurology · doi:10.1038/s41582-020-00435-y · Cited by 3,179
Lane, C. A., Hardy, J., & Schott, J. M. (2018) · European Journal of Neurology · doi:10.1111/ene.13439 · Cited by 2,616
Microglia in Alzheimer’s disease
Hansen, D. V., Hanson, J. E., & Sheng, M. (2018) · Journal of Cell Biology · doi:10.1083/jcb.201709069 · Cited by 1,935
Microglial signatures and their role in health and disease
Butovsky, O., & Weiner, H. L. (2018) · Nature Reviews Neuroscience · doi:10.1038/s41583-018-0057-5 · Cited by 1,046
Microbiota–gut–brain axis and its therapeutic applications in neurodegenerative diseases
Loh, J. S., Mak, W. Q., Tan, L. K. S., Ng, C. X., Chan, H. H., Yeow, S. H., Foo, J. B., Ong, Y. S., How, C. W., & Khaw, K. Y. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01743-1 · Cited by 1,193
Fricker, M., Tolkovsky, A. M., Borutaitė, V., Coleman, M. P., & Brown, G. C. (2018) · Physiological Reviews · doi:10.1152/physrev.00011.2017 · Cited by 1,148
Johnson, E. C. B., Dammer, E. B., Duong, D. M., Ping, L., Zhou, M., Yin, L., Higginbotham, L. A., Guajardo, A., White, B., Troncoso, J. C., et al. (2020) · Nature Medicine · doi:10.1038/s41591-020-0815-6 · Cited by 1,001
Microglia in Alzheimer's disease
Sarlus, H., & Heneka, M. T. (2017) · Journal of Clinical Investigation · doi:10.1172/jci90606 · Cited by 911
Clinical trials of new drugs for Alzheimer disease
Huang, L.-K., Chao, S.-P., & Hu, C.-J. (2020) · Journal of Biomedical Science · doi:10.1186/s12929-019-0609-7 · Cited by 702
Imaging the evolution and pathophysiology of Alzheimer disease
Jagust, W. (2018) · Nature Reviews Neuroscience · doi:10.1038/s41583-018-0067-3 · Cited by 604
Neuroinflammation in Alzheimer disease
Heneka, M. T., van der Flier, W. M., Jessen, F., Hoozemanns, J., Thal, D. R., Boche, D., Brosseron, F., Teunissen, C., Zetterberg, H., Jacobs, A. H., et al. (2025) · Nature Reviews Immunology · doi:10.1038/s41577-024-01104-7 · Cited by 638
Self-citationInflammatory Response in the CNS: Friend or Foe?
Sochocka, M., Diniz, B. S., & Leszek, J. (2017) · Molecular Neurobiology · doi:10.1007/s12035-016-0297-1 · Cited by 573
The road to restoring neural circuits for the treatment of Alzheimer's disease
Canter, R. G., Penney, J., & Tsai, L.-H. (2016) · Nature · doi:10.1038/nature20412 · Cited by 565
Microbiome–microglia connections via the gut–brain axis
Abdel-Haq, R., Schlachetzki, J. C. M., Glass, C. K., & Mazmanian, S. K. (2019) · Journal of Experimental Medicine · doi:10.1084/jem.20180794 · Cited by 471
TREM2, microglia, and neurodegenerative diseases
Yeh, F. L., Hansen, D. V., & Sheng, M. (2017) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2017.03.008 · Cited by 440
Linking Neuroinflammation and Neurodegeneration in Parkinson's Disease
Gelders, G., Baekelandt, V., & Van der Perren, A. (2018) · Journal of Immunology Research · doi:10.1155/2018/4784268 · Cited by 430
An early and late peak in microglial activation in Alzheimer’s disease trajectory
Fan, Z., Brooks, D. J., Okello, A., & Edison, P. (2017) · Brain · doi:10.1093/brain/aww349 · Cited by 438
Tau-targeting therapies for Alzheimer disease: Current status and future directions
Congdon, E. E., Ji, C., Tetlow, A. M., Jiang, Y., & Sigurdsson, E. M. (2023) · Nature Reviews Neurology · doi:10.1038/s41582-023-00883-2 · Cited by 371
CSF biomarkers of neuroinflammation and cerebrovascular dysfunction in early Alzheimer disease
Janelidze, S., Mattsson, N., Stomrud, E., Lindberg, O., Palmqvist, S., Zetterberg, H., Blennow, K., & Hansson, O. (2018) · Neurology · doi:10.1212/wnl.0000000000006082 · Cited by 359
Inflammation in Alzheimer’s disease: Lessons learned from microglia-depletion models
Spangenberg, E. E., & Green, K. N. (2017) · Brain, Behavior, and Immunity · doi:10.1016/j.bbi.2016.07.003 · Cited by 352
Microglia Phenotypes in Aging and Neurodegenerative Diseases
Wendimu, M. Y., & Hooks, S. B. (2022) · Cells · doi:10.3390/cells11132091 · Cited by 336
Ewers, M., Franzmeier, N., Suárez-Calvet, M., Morenas-Rodriguez, E., Caballero, M. A. A., Kleinberger, G., Piccio, L., Cruchaga, C., Deming, Y., Dichgans, M., et al. (2019) · Science Translational Medicine · doi:10.1126/scitranslmed.aav6221 · Cited by 327
Microbiota in neuroinflammation and synaptic dysfunction: a focus on Alzheimer’s disease
Bairamian, D., Sha, S., Rolhion, N., Sokol, H., Dorothée, G., Lemere, C. A., & Krantic, S. M. (2022) · Molecular Neurodegeneration · doi:10.1186/s13024-022-00522-2 · Cited by 326
Self-citationNeuroinflammation in Neurodegenerative Disorders-a Review
Schain, M., & Kreisl, W. C. (2017) · Current Neurology and Neuroscience Reports · doi:10.1007/s11910-017-0733-2 · Cited by 301
Neuroinflammation in Alzheimer’s Disease
Onyango, I. G., Jauregui, G. V., Čarná, M., Bennett, J. P., & Stokin, G. B. (2021) · Biomedicines · doi:10.3390/biomedicines9050524 · Cited by 330
The effects of microglia-associated neuroinflammation on Alzheimer’s disease
Wang, C., Zong, S., Cui, X., Wang, X., Wu, S., Wang, L., Liu, Y., & Lu, Z. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1117172 · Cited by 331
Sex-specific effects of microbiome perturbations on cerebral Aβ amyloidosis and microglia phenotypes
Dodiya, H. B., Kuntz, T., Shaik, S. M., Baufeld, C., Leibowitz, J., Zhang, X., Gottel, N., Zhang, X., Butovsky, O., Gilbert, J. A., et al. (2019) · Journal of Experimental Medicine · doi:10.1084/jem.20182386 · Cited by 288
Neuroinflammation across neurological diseases
Shi, F., & Yong, V. W. (2025) · Science · doi:10.1126/science.adx0043 · Cited by 325
Glial activation and inflammation along the Alzheimer’s disease continuum
Nordengen, K., Kirsebom, B.-E., Henjum, K., Selnes, P., Gísladóttir, B., Wettergreen, M., Torsetnes, S. B., Grøntvedt, G. R., Waterloo, K. K., Aarsland, D., et al. (2019) · Journal of Neuroinflammation · doi:10.1186/s12974-019-1399-2 · Cited by 274
Werry, E. L., Bright, F., Piguet, O., Ittner, L. M., Halliday, G. M., Hodges, J. R., Kiernan, M. C., Loy, C. T., Kril, J. J., & Kassiou, M. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20133161 · Cited by 298
Suárez-Calvet, M., Araque Caballero, M. Á., Kleinberger, G., Bateman, R. J., Fagan, A. M., Morris, J. C., Levin, J., Danek, A., Ewers, M., Haass, C., et al. (2016) · Science Translational Medicine · doi:10.1126/scitranslmed.aag1767 · Cited by 272
Microglial activation correlates in vivo with both tau and amyloid in Alzheimer’s disease
Dani, M., Wood, M., Mizoguchi, R., Fan, Z., Walker, Z., Morgan, R., Hinz, R., Biju, M., Kuruvilla, T., Brooks, D. J., et al. (2018) · Brain · doi:10.1093/brain/awy188 · Cited by 270
Neuroinflammation in mild cognitive impairment and Alzheimer’s disease: A meta-analysis
Bradburn, S., Murgatroyd, C., & Ray, N. J. (2019) · Ageing Research Reviews · doi:10.1016/j.arr.2019.01.002 · Cited by 277
Ismail, R., Parbo, P., Madsen, L. S., Hansen, A. K., Hansen, K. V., Schaldemose, J. L., Kjeldsen, P. L., Stokholm, M. G., Gottrup, H., Eskildsen, S. F., et al. (2020) · Journal of Neuroinflammation · doi:10.1186/s12974-020-01820-6 · Cited by 268
Clinical trials of new drugs for Alzheimer disease: a 2020–2023 update
Huang, L.-K., Kuan, Y.-C., Lin, H.-W., & Hu, C.-J. (2023) · Journal of Biomedical Science · doi:10.1186/s12929-023-00976-6 · Cited by 252
“The excessive accumulation of Aβ or other toxic compounds activates proinflammatory phenotypes, resulting in neuronal damage [29].”
BackgroundPET imaging of neuroinflammation in neurological disorders
Kreisl, W. C., Kim, M.-J., Coughlin, J. M., Henter, I. D., Owen, D. R., & Innis, R. B. (2020) · The Lancet Neurology · doi:10.1016/s1474-4422(20)30346-x · Cited by 254
Functional connectivity associated with tau levels in ageing, Alzheimer’s, and small vessel disease
Franzmeier, N., Rubinski, A., Neitzel, J., Kim, Y., Damm, A., Na, D. L., Kim, H. J., Lyoo, C. H., Cho, H., Finsterwalder, S., et al. (2019) · Brain · doi:10.1093/brain/awz026 · Cited by 243
Microglia and Alzheimer’s Disease
Merighi, S., Nigro, M., Travagli, A., & Gessi, S. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232112990 · Cited by 236
Targeting Neuroinflammation to Treat Alzheimer’s Disease
Ardura-Fabregat, A., Boddeke, E., Boza‐Serrano, A., Brioschi, S., Castro‐Gomez, S., Ceyzériat, K., Dansokho, C., Dierkes, T., Gelders, G., Heneka, M. T., et al. (2017) · CNS Drugs · doi:10.1007/s40263-017-0483-3 · Cited by 241
Microglia in Alzheimer’s Disease: Activated, Dysfunctional or Degenerative
Navarro, V., Sanchez-Mejias, E., Jimenez, S., Muñoz-Castro, C., Sanchez-Varo, R., Davila, J. C., Vizuete, M., Gutierrez, A., & Vitorica, J. (2018) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2018.00140 · Cited by 229
Stokholm, M. G., Iranzo, Á., Østergaard, K., Serradell, M., Otto, M., Svendsen, K. B., Garrido, A., Vilas, D., Borghammer, P., Santamaría, J., et al. (2017) · The Lancet Neurology · doi:10.1016/s1474-4422(17)30173-4 · Cited by 210
Meilandt, W. J., Ngu, H., Gogineni, A., Lalehzadeh, G., Lee, S.-H., Srinivasan, K., Imperio, J., Wu, T., Weber, M., Kruse, A. J., et al. (2020) · The Journal of Neuroscience · doi:10.1523/jneurosci.1871-19.2019 · Cited by 210
“…primarily beneficial in the context of AD pathology, elevated PET signal for ligands of the “neuroinflammation marker” TSPO have predicted better cognitive measures and slower AD progression in mice with -amyloid pathology and human patients, respectively (Hamelin et al., 2016; Focke et al., 2019).”
BackgroundCX3CL1/CX3CR1 signaling targets for the treatment of neurodegenerative diseases
Subbarayan, M. S., Joly‐Amado, A., Bickford, P. C., & Nash, K. R. (2021) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2021.107989 · Cited by 204
Parbo, P., Ismail, R., Hansen, K. V., Amidi, A., Mårup, F. H., Gottrup, H., Brændgaard, H., Eriksson, B. O., Eskildsen, S. F., Lund, T. E., et al. (2017) · Brain · doi:10.1093/brain/awx120 · Cited by 199
Glial Cell-Mediated Neuroinflammation in Alzheimer’s Disease
Al-Ghraiybah, N. F., Wang, J., Alkhalifa, A. E., Roberts, A. B., Raj, R., Yang, E., & Kaddoumi, A. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms231810572 · Cited by 212
Taipa, R., das Neves, S. P., Sousa, A. L., Fernandes, J., Pinto, C., Correia, A. P., Santos, E., Pinto, P. S., Carneiro, P., Costa, P., et al. (2019) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2018.12.019 · Cited by 205
Jian, M., Kwan, J., Bunting, M., Ng, R. C.-L., & Chan, K. H. (2019) · Journal of Neuroinflammation · doi:10.1186/s12974-019-1492-6 · Cited by 191
Targeting neuroinflammation in Alzheimer’s disease: from mechanisms to clinical applications
Si, Z.-Z., Zou, C.-J., Mei, X., Mei, X., Luo, H., Shen, Y., Hu, J., Li, X.-X., Wu, L., & Liu, Y. (2022) · Neural Regeneration Research · doi:10.4103/1673-5374.353484 · Cited by 199
Recent developments on PET radiotracers for TSPO and their applications in neuroimaging
Zhang, L., Hu, K., Shao, T., Hou, L., Zhang, S., Ye, W., Josephson, L., Meyer, J. H., Zhang, M., Vasdev, N., et al. (2020) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2020.08.006 · Cited by 195
Dupont, A.-C., Largeau, B., Santiago Ribeiro, M., Guilloteau, D., Tronel, C., & Arlicot, N. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18040785 · Cited by 182
“Longitudinal studies exhibited an increase in cortical-activated microglia during the course of AD [101,103,110].”
BackgroundInfluentialChandra, A., Valkimadi, P., Pagano, G., Cousins, O., Dervenoulas, G., Politis, M., & Initiative, A. D. N. (2019) · Human Brain Mapping · doi:10.1002/hbm.24782 · Cited by 197
The link between chronic pain and Alzheimer’s disease
Cao, S., Fisher, D. W., Yu, T., & Dong, H. (2019) · Journal of Neuroinflammation · doi:10.1186/s12974-019-1608-z · Cited by 195
Neutrophil hyperactivation correlates with Alzheimer's disease progression
Dong, Y., Lagarde, J., Xicota, L., Corne, H., Chantran, Y., Chaigneau, T., Crestani, B., Bottlaender, M., Potier, M., Aucouturier, P., et al. (2018) · Annals of Neurology · doi:10.1002/ana.25159 · Cited by 180
Self-citationRevolution of Alzheimer Precision Neurology. Passageway of Systems Biology and Neurophysiology
Hampel, H. J., (APMI), F. T. A. P. M. I., Toschi, N., Babiloni, C., Baldacci, F., Black, K. L., Bokde, A. L. W., Bun, R. S., Cacciola, F., Cavedo, E., et al. (2018) · Journal of Alzheimer s Disease · doi:10.3233/jad-179932 · Cited by 184
Self-citationHamelin, L., Lagarde, J., Dorothée, G., Potier, M. C., Corlier, F., Kuhnast, B., Caillé, F., Dubois, B., Fillon, L., Chupin, M., et al. (2018) · Brain · doi:10.1093/brain/awy079 · Cited by 177
Self-citationNovel Therapeutic Approaches for Alzheimer’s Disease: An Updated Review
Yu, T.-W., Lane, H., & Lin, C. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22158208 · Cited by 190
Soluble phospho-tau from Alzheimer’s disease hippocampus drives microglial degeneration
Sanchez-Mejias, E., Navarro, V., Jimenez, S., Sanchez-Mico, M., Sanchez-Varo, R., Nuñez-Diaz, C., Trujillo-Estrada, L., Davila, J. C., Vizuete, M., Gutierrez, A., et al. (2016) · Acta Neuropathologica · doi:10.1007/s00401-016-1630-5 · Cited by 175
Neuron secrete exosomes containing miR-9-5p to promote polarization of M1 microglia in depression
Xian, X., Cai, L.-L., Li, Y., Wang, R.-C., Xu, Y.-H., Chen, Y.-J., Xie, Y.-H., Zhu, X.-L., & Li, Y.-F. (2022) · Journal of Nanobiotechnology · doi:10.1186/s12951-022-01332-w · Cited by 169
Microglia and Astrocyte Function and Communication: What Do We Know in Humans?
Garland, E. F., Hartnell, I. J., & Boche, D. (2022) · Frontiers in Neuroscience · doi:10.3389/fnins.2022.824888 · Cited by 165
Early microglial activation and peripheral inflammation in dementia with Lewy bodies
Surendranathan, A., Su, L., Mak, E., Passamonti, L., Hong, Y. T., Arnold, R., Vázquez Rodríguez, P., Bevan-Jones, W. R., Brain, S. A. E., Fryer, T. D., et al. (2018) · Brain · doi:10.1093/brain/awy265 · Cited by 154
Neuroinflammation, gut microbiome, and Alzheimer's disease
Lin, L., Zheng, L. J., & Zhang, L. J. (2018) · Molecular Neurobiology · doi:10.1007/s12035-018-0983-2 · Cited by 147
Tronel, C., Largeau, B., Ribeiro, M. J., Guilloteau, D., Dupont, A.-C., & Arlicot, N. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18040802 · Cited by 161
Biomarkers used in Alzheimer’s disease diagnosis, treatment, and prevention
Mahaman, Y. A. R., Embaye, K. S., Huang, F., Li, L., Zhu, F., Wang, J.-Z., Liu, R., Feng, J., & Wang, X. (2022) · Ageing Research Reviews · doi:10.1016/j.arr.2021.101544 · Cited by 149
Millan, M. J. (2017) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2017.03.004 · Cited by 151
Neuroinflammatory responses in Alzheimer’s disease
Dansokho, C., & Heneka, M. T. (2017) · Journal of Neural Transmission · doi:10.1007/s00702-017-1831-7 · Cited by 146
Ewers, M., Biechele, G., Suárez‐Calvet, M., Sacher, C., Blume, T., Morenas‐Rodriguez, E., Deming, Y., Piccio, L., Cruchaga, C., Kleinberger, G., et al. (2020) · EMBO Molecular Medicine · doi:10.15252/emmm.202012308 · Cited by 133
Functional and structural damage of neurons by innate immune mechanisms during neurodegeneration
Ising, C., & Heneka, M. T. (2018) · Cell Death and Disease · doi:10.1038/s41419-017-0153-x · Cited by 140
Fu, W., Wang, X., & Ip, N. Y. (2018) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.8b00402 · Cited by 138
Fairley, L. H., Lai, K. O., Wong, J. H., Chong, W. J., Vincent, A. S., D’Agostino, G. A., Wu, X., Naik, R. R., Jayaraman, A., Langley, S. R., et al. (2023) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2209177120 · Cited by 132
[ 11 C]PK11195 binding in Alzheimer disease and progressive supranuclear palsy
Passamonti, L., Rodríguez, P. V., Hong, Y. T., Allinson, K. S. J., Bevan-Jones, W. R., Williamson, D., Jones, P. S., Arnold, R., Borchert, R. J., Surendranathan, A., et al. (2018) · Neurology · doi:10.1212/wnl.0000000000005610 · Cited by 115
Inflammatory mechanisms in neurodegeneration
Nichols, M. R., St‐Pierre, M., Wendeln, A., Makoni, N. J., Gouwens, L. K., Garrad, E. C., Sohrabi, M., Neher, J. J., Tremblay, M., & Combs, C. K. (2019) · Journal of Neurochemistry · doi:10.1111/jnc.14674 · Cited by 129
Fard, M. T., & Stough, C. K. K. (2019) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2019.00056 · Cited by 124
The role of innate immunity in Alzheimer's disease
Ennerfelt, H. E., & Lukens, J. R. (2020) · Immunological Reviews · doi:10.1111/imr.12896 · Cited by 124
In vivo molecular imaging of neuroinflammation in Alzheimer's disease
Chaney, A. M., Williams, S. R., & Boutin, H. (2018) · Journal of Neurochemistry · doi:10.1111/jnc.14615 · Cited by 119
Pharmacological approaches to mitigate neuroinflammation in Alzheimer’s disease
Uddin, M. S., Kabir, M. T., Mamun, A. A., Barreto, G. E., Rashid, M., Perveen, A., & Ashraf, G. M. (2020) · International Immunopharmacology · doi:10.1016/j.intimp.2020.106479 · Cited by 121
The role of the immune system in Alzheimer’s disease
Wu, K., Zhang, Y.-R., Huang, Y., Dong, Q., Tan, L., & Yu, J. (2021) · Ageing Research Reviews · doi:10.1016/j.arr.2021.101409 · Cited by 119
Role of the Extracellular Matrix in Alzheimer’s Disease
Sun, Y., Xu, S., Jiang, M., Liu, X., Yang, L., Bai, Z., & Yang, Q. (2021) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2021.707466 · Cited by 119
Microglial activation in early Alzheimer trajectory is associated with higher gray matter volume
Femminella, G. D., Dani, M., Wood, M., Fan, Z., Calsolaro, V., Atkinson, R., Edginton, T. L., Hinz, R., Brooks, D. J., & Edison, P. (2019) · Neurology · doi:10.1212/wnl.0000000000007133 · Cited by 109
Mullane, K., & Williams, M. J. (2020) · Biochemical Pharmacology · doi:10.1016/j.bcp.2020.113945 · Cited by 109
PET Neuroimaging of Alzheimer's Disease: Radiotracers and Their Utility in Clinical Research
Bao, W., Xie, F., Zuo, C., Guan, Y., & Huang, Y. H. (2021) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2021.624330 · Cited by 102
Varatharajah, Y., Ramanan, V. K., Iyer, R. K., Vemuri, P., Initiative, A. D. N., Weiner, M. W., Aisen, P., Petersen, R. C., Jack, C. R., Saykin, A. J., et al. (2019) · Scientific Reports · doi:10.1038/s41598-019-38793-3 · Cited by 108
Molecular imaging of neuroinflammation in Alzheimer's disease and mild cognitive impairment
Knezevic, D., & Mizrahi, R. (2018) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2017.05.007 · Cited by 97
Is Alzheimer’s disease an inflammasomopathy?
Pereira, C., Santos, A. E., Moreira, P. I., Pereira, A. C., Sousa, F. J., Cardoso, S. M., & Cruz, M. T. (2019) · Ageing Research Reviews · doi:10.1016/j.arr.2019.100966 · Cited by 95
Patir, A., Shih, B., McColl, B. W., & Freeman, T. C. (2019) · Glia · doi:10.1002/glia.23572 · Cited by 90
Best, L. A., Ghadery, C., Pavese, N., Tai, Y., & Strafella, A. P. (2019) · Current Neurology and Neuroscience Reports · doi:10.1007/s11910-019-0934-y · Cited by 93
Hagens, M., Golla, S. S. V., Wijburg, M., Yaqub, M., Heijtel, D., Steenwijk, M., Schober, P., Brevé, J., Schuit, R., Reekie, T., et al. (2018) · Journal of Neuroinflammation · doi:10.1186/s12974-018-1352-9 · Cited by 79
In vivo Imaging of Glial Activation in Alzheimer's Disease
Edison, P., Donat, C. K., & Sastre, M. (2018) · Frontiers in Neurology · doi:10.3389/fneur.2018.00625 · Cited by 88
Kynurenine Pathway Metabolites as Biomarkers in Alzheimer’s Disease
Liang, Y., Xie, S., He, Y., Xu, M., Qiao, X., Zhu, Y. H., & Wu, W. (2022) · Disease Markers · doi:10.1155/2022/9484217 · Cited by 92
The old guard: Age-related changes in microglia and their consequences
Costa, J., Martins, S., Ferreira, P. A., Cardoso, A. M., Guedes, J. R., Peça, J., & Cardoso, A. L. (2021) · Mechanisms of Ageing and Development · doi:10.1016/j.mad.2021.111512 · Cited by 88
Candesartan ameliorates brain inflammation associated with Alzheimer's disease
Torika, N., Asraf, K., Apte, R. N., & Fleisher‐Berkovich, S. (2018) · CNS Neuroscience & Therapeutics · doi:10.1111/cns.12802 · Cited by 82
Shen, Z., Bao, X., & Wang, R. (2018) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2018.00314 · Cited by 77
In Vivo TSPO Signal and Neuroinflammation in Alzheimer’s Disease
Tournier, B. B., Tsartsalis, S., Ceyzériat, K., Garibotto, V., & Millet, P. (2020) · Cells · doi:10.3390/cells9091941 · Cited by 79
Higher CSF sTREM2 attenuates ApoE4-related risk for cognitive decline and neurodegeneration
Franzmeier, N., Suárez‐Calvet, M., Frontzkowski, L. K., Moore, A. M., Hohman, T. J., Morenas‐Rodríguez, E., Nuscher, B., Shaw, L. M. J., Trojanowski, J. Q., Dichgans, M., et al. (2020) · Molecular Neurodegeneration · doi:10.1186/s13024-020-00407-2 · Cited by 78
Sridharan, S., Lepelletier, F.-X., Trigg, W., Banister, S. D., Reekie, T. A., Kassiou, M., Gerhard, A., Hinz, R., & Boutin, H. (2016) · Molecular Imaging and Biology · doi:10.1007/s11307-016-0984-3 · Cited by 78
Mullin, S., Stokholm, M. G., Hughes, D. A., Mehta, A. B., Parbo, P., Hinz, R., Pavese, N., Brooks, D. J., & Schapira, A. H. V. (2020) · Movement Disorders · doi:10.1002/mds.28375 · Cited by 78
Bevan-Jones, W. R., Surendranathan, A., Passamonti, L., Rodríguez, P. V., Arnold, R. J., Mak, E., Su, L., Coles, J., Fryer, T. D., Hong, Y. T., et al. (2017) · BMJ Open · doi:10.1136/bmjopen-2016-013187 · Cited by 75
Cerami, C., Iaccarino, L., & Perani, D. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18050993 · Cited by 75
Rivera-Escalera, F., Pinney, J. J., Owlett, L., Ahmed, H., Thakar, J., Olschowka, J. A., Elliott, M. R., & O’Banion, M. K. (2019) · Journal of Neuroinflammation · doi:10.1186/s12974-019-1645-7 · Cited by 75
Zhao, Q., Li, J., Feng, J., Wang, X., Liu, Y., Wang, F., Liu, L., Jin, B., Lin, M. S., Wang, Y., et al. (2025) · Nature Metabolism · doi:10.1038/s42255-025-01379-7 · Cited by 86
Fleiss, B., Wong, F. Y., Brownfoot, F., Shearer, I. K., Baud, O., Walker, D. W., Gressèns, P., & Tolcos, M. (2019) · Frontiers in Endocrinology · doi:10.3389/fendo.2019.00188 · Cited by 79
Metadata
- Authors
- Hamelin, L., Lagarde, J., Dorothée, G., Leroy, C., Labit, M., Comley, R. A., de Souza, L. C., Corne, H., Dauphinot, L., Bertoux, M., Dubois, B., Gervais, P., Colliot, O., Potier, M. C., Bottlaender, M., Sarazin, M., & the Clinical IMABio3 team
- Affiliations
- Centre National de la Recherche Scientifique (FR)
- Inserm (FR)
- Centre d'Acquisition et de Traitement des Images (FR)
- F. Hoffmann-La Roche AG (CH)
- Assistance Publique – Hôpitaux de Paris (FR)
- ORCID
- Venue
- Brain
- Publisher
- Oxford University Press (OUP)
- Published
- 2016-03-15
- Volume
- 139
- Issue
- 4
- Pages
- 1252-1264
- ISSN
- 0006-8950 (ISSN-L)
- 1460-2156
- OpenAlex
- W2298656843
- Cited by
- 519
- References
- 41
- Citations by year
- 2026: 38 · 2025: 48 · 2024: 71 · 2023: 59 · 2022: 47 · 2021: 47 · 2020: 51 · 2019: 51 · 2018: 57 · 2017: 39 · 2016: 10
- FWCI
- 28.85
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Brain (publishedVersion)
- PubMed (publishedVersion)
- HAL (submittedVersion)
- HighWire Press Open Archive (submittedVersion)
- Zenodo (CERN European Organization for Nuclear Research) (submittedVersion, cc-by)
- Funders
- European Commission (2007–2013, FP7 2007-2013, FP7/2007, 278850)
- Université Paris Descartes
- Topics
- Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Keywords
- Alzheimer's disease, microglial activation, translocator protein (TSPO), [18F]DPA-714, neuroinflammation, prodromal Alzheimer's disease, amyloid imaging, Pittsburgh compound B, clinical progression, amyloidosis, gray matter volume, temporoparietal cortex, frontal cortex, cognitive decline
- MeSH terms
- Aged, Aged, 80 and over, Alzheimer Disease, Brain, Female, Fluorine Radioisotopes, Follow-Up Studies, Humans, Longitudinal Studies, Male, Middle Aged, Prospective Studies, Pyrazoles, Pyrimidines, Cohort Studies, Microglia, Positron-Emission Tomography
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
